SANUWAVE Health, Inc NT 10-Q, filed Nov 17, 2020
SANUWAVE Health, Inc. (SNWV)
NT 10-Q
2020-11-17
For: 2020-09-30
View Original
Added on
October 19, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
(Check one):
|
|
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
|
|
|
For Period Ended: September 30, 2020
|
|
|
|
☐ Transition Report on Form 10-K
|
|
|
|
☐ Transition Report on Form 20-F
|
|
|
|
☐ Transition Report on Form 11-K
|
|
|
|
☐ Transition Report on Form 10-Q
|
|
|
|
☐ Transition Report on Form N-SAR
|
|
|
|
For the Transition Period Ended:
|
|
|
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
SANUWAVE Health, Inc.
Full Name of Registrant
Former Name if Applicable
3360 Martin Farm Road, Suite 100
Address of Principal Executive Office (Street and Number)
Suwanee, Georgia
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
|
☒
|
|
(a)
|
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
|
(b)
|
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
|
(c)
|
|
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)
The compilation, verification and review by management of the information and disclosure required to be presented in the Form 10-Q for the period ended September 30, 2020 (the “Report”) requires additional time which renders the timely filing of
the Report impracticable without undue hardship and expense to the Registrant. In accordance with Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended, the Registrant intends to file the Report on or prior to the fifth
calendar day following the prescribed due date.
PART IV — OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
Kevin A. Richardson, II
|
(770)
|
|
419-7525
|
|
|
(Name)
|
(Area Code)
|
|
(Telephone Number)
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no, identify report(s). Yes ☐ No ☒
In connection with the Registrant’s acquisition of the UltraMIST assets from Celularity Inc. on August 6, 2020, the Registrant has not timely filed a Form 8-K/A containing audited historical financial statements of
the acquired business assets. The audited financial statements are required under Rule 3-05 of Regulation S-X.
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☒ No ☐
|
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
The Registrant expects to report (i) revenue for the quarter ended September 30, 2020 of approximately $1.97 million compared to $197,640 for the quarter ended September 30, 2019, and (ii) a net loss for the quarter ended
September 30, 2020 of approximately $6.2 million compared to $2.7 million for the quarter ended September 30, 2019. The changes are primarily due to the acquisition of the UltraMIST assets of Celularity Inc. on August 6, 2020.
The financial results presented above for the quarter ended September 30, 2020 reflect preliminary estimates of the Registrant’s results of operations and anticipated changes for the corresponding prior period as of the
date of the filing of the Form 12b-25. These estimates are subject to change upon the completion of the reporting process and review of the Registrant’s financial statements, and actual results may vary significantly from these estimates.
Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements, which are based on the Registrant’s current expectations, estimates, and projections about the Registrant’s and its subsidiaries’ businesses and
prospects, as well as management’s beliefs, and certain assumptions made by management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “should,” “will” and variations of these words are intended
to identify forward-looking statements. Such statements speak only as of the date hereof and are subject to change. The Registrant undertakes no obligation to revise or update publicly any forward-looking statements for any reason. These statements
include, but are not limited to, statements about the anticipated timing of the filing of the Registrant’s Form 10-Q for the quarterly period ended September 30, 2020, and the Registrant’s anticipated financial results for such period. Such
statements are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Accordingly, actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various
factors. Important factors that may cause such differences include, but are not limited to, those risks and uncertainties disclosed under the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in the Registrant’s most recent Form 10-K and Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and similar disclosures in subsequent reports filed with the SEC.
SANUWAVE Health, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date
|
|
November 17, 2020
|
|
By
|
|
/s/ Kevin A. Richardson, II
|
|
|
|
|
Kevin A. Richardson
|
|||
|
|
|
|
Chief Executive Officer
|